قالب وردپرس درنا توس
Home / Business / Sacramento was chosen as the testing site for the COVID-19 vaccine

Sacramento was chosen as the testing site for the COVID-19 vaccine



Sacramento has been selected as a location for a COVID-19 vaccine trial. Both UC Davis Medical Center and Kaiser Permanente are participating in vaccine trials through a partnership with Pfizer. The trial will involve 120 countries with a goal of involving 30,000 applicants worldwide. “What we want the community to know is that this is really important research. It’s the first step in developing a vaccine for COVID,” said UC Davis Medical School Dean Allison Brashear. UC Davis Medical Center explained that is focusing on enrolling participants who are Latinx and Black – communities disproportionately affected by COVID-1

9. “Anyone 18 to 55 is in the first group and then immediately after that will be individuals over 55 years old. And, we want people who are in reasonable health, “Brashear explained.” Kaiser Permanente is looking for applicants who are between 18 and 85 years old and generally healthy, but who are considered at high risk due to employment, a situation “We are not injecting any of the viral proteins ourselves. We are not injecting any viruses into individuals,” said Nicola Klein, of the Kaiser Permanente Vaccine Research Center. . “But MRNA – what is called nucleic acid MRNA technology – and that includes DNA vaccines, which you may have heard of as well. This is a new vaccine technology. Now there are no licensed vaccines that are developed using “But it’s genetic material. It can no longer copy or do anything on its own.” Kaiser Permanente is also part of another COVID-19 vaccine trial, co-developed by the National Institute of Allergy and Infectious Diseases. and Moderna.UC Davis explained if the candidate vaccine success continues, the regulatory review could take place as early as October.If approved, Pfizer and BioNTech plan to supply up to 100 million doses by the end of 2020 and approximately 1.3 billion doses by end of 2021.

Sacramento has been selected as a location for a COVID-19 vaccine trial. Both UC Davis Medical Center and Kaiser Permanente are participating in the vaccine trial through a partnership with Pfizer.

The trial will involve 120 countries with a goal of involving 30,000 applicants worldwide.

“What we want the community to know is that this is really important research. It’s the first step in developing a vaccine for COVID,” said UC Davis Allison Brashear, Dean of UC Medical School.

UC Davis Medical Center explained that it is focusing on enrolling participants who are Latinx and Black – communities disproportionately affected by COVID-19.

“Anyone 18 to 55 is in the first group and then immediately after that there will be individuals over 55. And, we want people who are in reasonable health,” Brashear explained.

Kaiser Permanente is looking for applicants who are between 18 and 85 years old and generally healthy but considered at high risk due to employment, a living situation or part of a community considered at risk for COVID-19.

“We are not injecting any of the viral proteins ourselves. We are not injecting any viruses into individuals,” said Nicola Klein, with the Kaiser Permanente Vaccine Research Center. “But MRNA – what is called nucleic acid MRNA technology – and that includes DNA vaccines, which you may have heard of as well. This is a new vaccine technology. Now there are no licensed vaccines that are developed using “This technology. But it’s genetic material. It can no longer copy itself or do anything on its own.”

Kaiser Permanente is also part of another trial for COVID-19 vaccines, co-developed by the National Institute of Allergy and Infectious and Modern Diseases.

UC Davis explained that if the vaccine candidate’s success continues, the regulatory review could take place as early as October.

If approved, Pfizer and BioNTech plan to supply up to 100 million doses by the end of 2020 and approximately 1.3 billion doses by the end of 2021.


Source link